Development of a single-shot subunit vaccine for HIV-1 .3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120

被引:24
作者
Cleland, JL
Barron, L
Daugherty, A
Eastman, D
Kensil, C
Lim, A
Weissburg, RP
Wrin, T
Vennari, J
Powell, MF
机构
[1] GENENTECH INC, DEPT PHARMACEUT RES & DEV, San Francisco, CA 94080 USA
[2] GENENTECH INC, DEPT CELL BANKING & CHARACTERIZAT, San Francisco, CA 94080 USA
[3] GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA
[4] CAMBRIDGE BIOTECH CORP, WORCESTER, MA USA
关键词
D O I
10.1021/js960329b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
HIV-1 prophylaxis may require ''sterilizing immunity'' (i.e., the prevention of infection), and this is likely to demand a vaccine that gives high, long-lasting antibody titers. Although it is known that vaccine adjuvants and immunization schedule affect the magnitude of the immune response, there are few reports on antibody decay rates and persistence. Guinea pigs were immunized with recombinant gp120 using different adjuvants and immunization schedules, and the anti-gp120 and HIV-1 neutralization titers were determined over time following the last booster immunization. As observed previously in the literature, a longer time between boosting gave higher titers, with a slight increase in the decay half-life as the booster was spaced farther out from the primary immunization. The decay rate of the antibody titers showed surprisingly little effect of adjuvant, except for sustained-release polymer-based formulations. Adjuvants that gave high titers initially after boosting showed the greatest persistence of antibody titers (persistence defined as the residual titers at long times). These data show that high, long-lasting titers may be achieved by using sustained-release formulations, and these are likely the prime vaccine candidates for prophylaxis requiring prolonged sterilizing immunity.
引用
收藏
页码:1350 / 1357
页数:8
相关论文
共 47 条
[1]   EFFECT OF DOSE AND IMMUNIZATION SCHEDULE ON IMMUNE-RESPONSE OF BABOONS TO RECOMBINANT GLYCOPROTEIN-120 OF HIV-1 [J].
ANDERSON, KP ;
LUCAS, C ;
HANSON, CV ;
LONDE, HF ;
IZU, A ;
GREGORY, T ;
AMMANN, A ;
BERMAN, PW ;
EICHBERG, JW .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (06) :960-969
[2]   A COMPARISON OF COMMERCIALLY AVAILABLE ADJUVANTS FOR USE IN RESEARCH [J].
BENNETT, B ;
CHECK, IJ ;
OLSEN, MR ;
HUNTER, RL .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 153 (1-2) :31-40
[3]   Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1 [J].
Berman, PW ;
Murthy, KK ;
Wrin, T ;
Vennari, JC ;
Cobb, EK ;
Eastman, DJ ;
Champe, M ;
Nakamura, GR ;
Davison, D ;
Powell, MF ;
Bussiere, J ;
Francis, DP ;
Matthews, T ;
Gregory, TJ ;
Obijeski, JF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :52-59
[4]   NEUTRALIZATION OF MULTIPLE LABORATORY AND CLINICAL ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) BY ANTISERA RAISED AGAINST GP120 FROM THE MN ISOLATE OF HIV-1 [J].
BERMAN, PW ;
MATTHEWS, TJ ;
RIDDLE, L ;
CHAMPE, M ;
HOBBS, MR ;
NAKAMURA, GR ;
MERCER, J ;
EASTMAN, DJ ;
LUCAS, C ;
LANGLOIS, AJ ;
WURM, FM ;
GREGORY, TJ .
JOURNAL OF VIROLOGY, 1992, 66 (07) :4464-4469
[5]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[6]   COMPARISON OF THE IMMUNE-RESPONSE TO RECOMBINANT GP120 IN HUMANS AND CHIMPANZEES [J].
BERMAN, PW ;
EASTMAN, DJ ;
WILKES, DM ;
NAKAMURA, GR ;
GREGORY, TJ ;
SCHWARTZ, D ;
GORSE, G ;
BELSHE, R ;
CLEMENTS, ML ;
BYRN, RA .
AIDS, 1994, 8 (05) :591-601
[7]   IMPAIRED RESPONSE TO RECOMBINANT HEPATITIS-B VACCINE IN HIV-INFECTED PERSONS [J].
BRUGUERA, M ;
CREMADES, M ;
SALINAS, R ;
COSTA, J ;
GRAU, M ;
SANS, J .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1992, 14 (01) :27-30
[8]  
Cabasso V J, 1978, Dev Biol Stand, V40, P231
[9]  
CLELAND JL, 1994, AIDS RES HUM RETROV, V10, pS21
[10]  
CLELAND JL, 1995, VACCINE DESIGN SUBUN, P439